 |
Medytox.(photo=medytox) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Medytox announced on the 26th that it has signed a contract with Brazilian pharmaceutical company B.L.A. to supply botulinum toxin drugs worth a total of $7,300 million (about KRW 98 billion, based on MOQ) over five years. In the future, Medytox will supply botulinum toxin drugs to BLAU, and BLAU will sell Medytox's botulinum toxin drugs to the Brazilian region.
The contract was signed under strategic consultation after exploring a long-term supply contract with Medytox when BLAU acquired Medytox's existing Brazilian partner Laboratorio Quimico e Farmaceutico Bergamo Ltda.
Medytox entered the Brazilian market in 2010 with Medytoxin (export name Botullift) developed for the first time in Korea, and has continued to grow since then and exported more than 20 billion won last year. Brazil is an important exporter, accounting for about 30% of Medytox's toxin exports (61 billion won) last year.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
